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ZUSAMMENFASSUNG 
Neben der hohen individuellen Belastung für den Patienten, stellen die chronischen 
Nierenerkrankungen eine relevante Herausforderung für die Gesundheitssysteme dar. Die 
chronische Niereninsuffizienz ist sowohl mit dem Risiko des Fortschreitens der 
Niereninsuffizienz bis zur Dialysepflicht als auch mit der Entwicklung kardiovaskulärer 
Komplikationen verbunden. Dabei stellt das Vorliegen einer hohen Proteinurie einen der 
wenigen etablierten Risikoindikatoren für die Entwicklung einer terminalen 
Niereninsuffizienz mit erhöhter kardiovaskulärer Morbidität und Mortalität dar. Das Ziel 
dieser Doktorarbeit war es, neue Gentranskripte zu identifizieren, die an der Entwicklung von 
humanen Nierenerkrankungen beteiligt sind, indem Genexpressionsprofile der Europäischen 
Renalen cDNA Bank-Kröner-Fresenius-Biopsiebank (ERCB-KFB) mit den neuesten 
technischen und bioinformatischen Methoden analysiert wurden. Da das Vorhandensein von 
Proteinurie von hoher klinischer Relevanz ist, konzentrierten sich unsere Studien 
hauptsächlich auf erworbene proteinurische Glomerulopathien, wie Minimal Change Disease 
(MCD), fokal-segmentale Glomerulosklerose (FSGS) und membranöse 
Glomerulonephropathie (MGN). 
Zunächst generierten wir einen humanen renalen Datensatz an glomerulär überexprimierten 
Gentranskripten, REGGED, mit 677 Genen von bereits bekannter und unbekannter 
glomerulärer Relevanz. Dieser Datensatz war die umfassendste humane glomeruläre 
Genexpressionsdatenbank zum Zeitpunkt ihrer Veröffentlichung. 
Chronische Hypoxie trägt zur Entstehung von Nierenfibrose bei und es wird vermutet, dass 
sie an der Entwicklung der Nephrosklerose (NSC), der sogenannten hypertensiven 
Nephropathie, beteiligt ist. Wir haben spezifische Studien durchgeführt, um die biologischen 
Prozesse einer Hypoxie-bedingten Nierenschädigung bei NSC zu verstehen. Dabei fanden wir 
das Hypoxie-induzierte Gentranskript Chemokin C-X-C-Motivrezeptor 4 (CXCR4) 
prominent in Glomeruli von NSC-Patienten induziert. In NSC-Biopsien zeigte CXCR4, ein 
bekanntes Zielgen der Hypoxie-induzierten Transkriptionsfaktoren, immunhistochemisch eine 
starke Positivität in Podozyten, die auch eine nukleäre Positivität für den Hypoxie-
induzierbaren Faktor-1α (HIF1α) aufwiesen. Diese Daten weisen auf eine transkriptionelle 
Aktivität von HIF1α in Glomeruli bei NSC hin. 
In einem weiteren Schritt wurde mit unserem REGGED-Datensatz ein glomeruläres 
Gentranskript mit hoher Induktion in den progressiven Glomerulopathien FSGS und MGN 
selektiert. Unter den matrizellulären Molekülen war Periostin (POSTN) am stärksten in 
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diesen progressiven und sklerosierenden Glomerulopathien induziert.  Wir konnten erstmals 
zeigen, dass Periostin in gesunden Glomeruli konstitutiv exprimiert ist und bei Entwicklung 
einer chronischen Niereninsuffizienz stark induziert wird. So zeigte seine Expression eine 
negative Korrelation mit der klinisch gemessenen Nierenfunktion bei humanen 
proteinurischen Glomerulopathien. Stimulationsexperimente an murinen Mesangialzellen mit 
TGF-β1, einem bekannten Stimulator für die Periostin-Expression in anderen Zellen, führten 
zu einer robusten Induktion von Periostin. Menschliche und murine Mesangialzellen, die mit 
Periostin inkubiert wurden, reagierten mit Proliferation. Nieren von Periostin-defizienten 
Mäusen zeigten vergrösserte Glomeruli und wiesen ein proliferatives Mesangium auf. Die 
Serumproben dieser adulten Periostin-defizienten Mäuse zeigten eine signifikant abnehmende 
Nierenfunktion, was auf eine Relevanz von Periostin in der Nierenentwicklung hinweist. Wir 
nutzten die etablierten Techniken zur Periostin-Analyse auch zur Untersuchung dieses 
matrizellulären Moleküls bei der peritonealen Fibrose bei niereninsuffizienten Patienten, die 
mit Peritonealdialyse behandelt wurden. In diesen Patienten fand sich Periostin in fibrotischen 
Bereichen des Peritoneums stark positiv gefärbt, und auch die Periostinkonzentration stieg im 
Dialysat mit Dauer der Peritonealdialysetherapie signifikant an. 
In Patienten mit spezifischen proteinurischen Nierenerkrankungen mit primärer 
Podozytendysfunktion kann die Therapie mit Glukokortikoiden zu einer prompten 
Verbesserung der Proteinurie führen. Dies weist auf einen direkten glomerulären 
Glukokortikoideffekt in diesen Podozytopathien hin. Auf der Suche nach einem glomerulären 
REGGED-Gentranskript mit bekannter glukokortikoid-abhängiger Genregulation fanden wir 
TSC22D3 bei proteinurischen Glomerulopathien supprimiert exprimiert. In humanen Nieren, 
in diesem Fall Transplantatnephrektomien, waren Podozyten und einige distale Tubuli 
immunhistochemisch positiv für TSC22D3 gefärbt. Die Western-Blot-Analysen zeigten eine 
Expression von TSC22D3 in humanen und murinen Podozyten. Die TSC22D3-Expression 
konnte in diesen Zellen dosisabhängig durch Zugabe von Glukokortikoid gesteigert werden. 
Zum besseren Verständnis der Rolle von TSC22D3 wurden Isoformen des TSC22D3-
Drosophila-Homologs bunched in Drosophila-Larven unter verschiedenen Fütterungs-
bedingungen untersucht. Hierbei zeigten sich Hinweise auf eine funktionelle Interferenz 
zwischen den verschiedenen Isoformen. 
Zusammenfassend haben wir eine hochspezifische glomeruläre Genexpressionsdatenbank 
etabliert und für Untersuchungen zur Pathogenese der humanen Nephrosklerose, der 
matrizellulären Biologie bei progressiven Nierenerkrankungen und zur Podozytenbiologie bei 
steroid-sensitiven Glomerulopathien  genutzt.  
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SUMMARY 
Beside considerable restriction to the patient’s individual life and overall poor prognosis, 
chronic kidney disease (CKD) also burdens the health care system with high costs. CKD 
patients are prone for progression to end-stage renal failure and development of 
cardiovascular complication.  Proteinuria is one of the few established prognostic indicators 
for disease progression, cardiovascular morbidity and overall mortality. The aim of this PhD 
study was to identify novel renal gene transcripts involved in human CKD development by 
analyzing gene expression profiles from samples of the European Renal cDNA Bank-Kröner-
Fresenius Biopsy Bank (ERCB-KFB) using most recent technical and bioinformatical tools. 
As proteinuria is of specific clinical relevance our studies mainly focused on acquired 
proteinuric glomerulopathies namely minimal change disease (MCD), focal-segmental 
glomerulosclerosis (FSGS) and membranous glomerulonephropathy (MGN). 
Using a comparative strategy of microdissected nephron segments, we first established a 
human renal glomerulus-enriched gene expression dataset (REGGED) containing 677 genes 
of known and previously unknown glomerular relevance. This dataset was proven to be the 
most comprehensive human glomerular gene expression database at the time of publication.   
Chronic hypoxia contributes to renal fibrosis and was hypothesized to be involved in 
nephrosclerosis (NSC), also known as hypertensive nephropathy. We performed specific 
studies to comprehend the biological processes of hypoxia-related renal injury in NSC. We 
found a hypoxia-associated gene expression profile in glomeruli from NSC patients not seen 
in controls. The expression of chemokine C-X-C motif receptor 4 (CXCR4), a known gene 
regulated by hypoxia-induced transcription factors (HIF), was found to be prominently 
induced in NSC glomeruli. In NSC biopsies, CXCR4 protein showed an enhanced staining in 
podocytes of NSC glomeruli, associated with a nuclear positivity of the hypoxia-inducible 
factor-1α (HIF1α) suggesting a transcriptional activity of HIF1α. 
In a further step, our REGGED dataset was used to select a glomerular gene transcript with 
highest induction in progressive proteinuric glomerulopathies, namely FSGS and MGN. 
Among matricellular genes, periostin (POSTN) was found to be maximally induced in these 
progressive, sclerosing glomerulopathies. In further studies, periostin was found to be 
constitutively expressed in healthy glomeruli with a maximal induction with development of 
renal failure. Its expression correlated negatively with renal function in human proteinuric 
glomerulopathies. Stimulation experiments performed on murine mesangial cells with TGF-
β1, a known stimulator for periostin expression, resulted in a robust induction of periostin. 
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Human and murine mesangial cells exposed to periostin responded with proliferation. In 
kidneys from periostin-deficient mice, glomeruli were enlarged and showed a proliferative 
mesangium. Serum data from these adult periostin-deficient mice indicated a reduced renal 
function suggesting developmental relevance of periostin in the kidney. We took the studies 
on the matricellular molecule periostin further to peritoneal fibrosis in peritoneal dialysis 
patients. In these patients with end-stage renal disease, periostin was positively stained in 
fibrotic areas of the peritoneum and periostin concentrations in the dialysate significantly 
increased with time on treatment. 
In patients with specific proteinuric renal diseases with primary podocyte dysfunction, the 
treatment with glucocorticoids may lead to a prompt improvement of proteinuria. This 
suggests a direct glomerular effect of glucocorticoids in such podocytopathies. Seeking for a 
glomerulus-enriched gene transcript with known glucocorticoid-induced gene regulation, we 
found TSC22D3 to be repressed in human proteinuric glomerulopathies. In human kidney 
specimen, i.e. transplant nephrectomies, podocytes and some distal tubules were stained 
positive for TSC22D3. Western blot analysis showed expression of TSC22D3 in human and 
murine podocytes. Its expression could be induced by application of glucocorticoids in a 
dose-dependent manner. To better understand the biology of TSC22D3, isoforms of the 
TSC22D3 drosophila homolog bunched were studied in drosophila larvae under various 
feeding conditions, suggesting a functional interference among the different isoforms. 
 
In conclusion, we generated a unique glomerulus-enriched gene expression dataset and used 
this for studies on the pathobiology of glomerular nephrosclerosis, matricellular biology in 
progressive glomerulopathies and glucocorticoid-dependent glomerular gene transcripts in 
steroid-sensitive glomerulopathies.   
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INTRODUCTION 
1. CHRONIC KIDNEY DISEASE  
The kidneys perform several important tasks, including the removal of excess fluid and 
metabolic waste products such as urea, creatinine, uric acid and toxins from the blood and the 
maintenance of homeostasis [1]. This includes the regulation of electrolyte levels such as 
calcium, sodium and potassium, and the control of acid-base balance. Certain essential 
hormones are produced by the kidney such as calcitriol (1,25-dihydroxy-vitamin D3), 
erythropoietin (EPO) and renin. The latter plays a major role in controlling blood volume and 
blood pressure by regulation of the angiotensin aldosterone system. Each human kidney is 
composed of about one million nephrons. The nephron forms the working unit of the kidney 
and consists of a renal body (the glomerulus with a tuft of capillaries and the Bowman’s 
capsule) and an associated renal tubule system (containing the proximal tubule, loop of Henle, 
distal and collecting tubule). These organs filtrate about 180 liters of primary urine daily from 
the glomerular capillaries into the renal tubules and produce approximately 2 liters of urine. 
The urine results from glomerular filtration and following tubular reabsorption of sodium, 
water and specific solutes and secretion of metabolism products and other substances [2]. 
Whereas glomerular filtration is mainly influenced by the netto sum of various pressures and 
resistances, the tubular reabsorption includes passive and active mechanisms through osmosis 
and transporters (e.g. ENaC; SGLT1/2; GLUT1/2) [3-6]. The glomerular filtration barrier 
consists essentially of three layers: the capillary endothelium with its glycocalyx, the 
negatively charged basement membrane and the podocytes, which also form the inner wall of 
the Bowman’s capsule [7]. While the basement membrane consists of collagen and 
glycoproteins, the podocytes form between their foot processes a slit diaphragm. The 
filtration barrier appears to be permeable only to molecules up to a certain size, i.e. smaller 
than albumin.  
 
The glomerular filtration rate (GFR), an important clinical parameter to define renal function, 
is defined as the volume of blood that is filtered by all glomeruli per unit time. It is a measure 
for the elimination capacity of the kidneys and a GFR greater than 90 milliliters per minute is 
considered as “normal” in most populations. Clinical guidelines recommend estimating GFR 
(eGFR) by a measurement of serum creatinine, a waste product created by the muscles. The 
eGFR calculation should be based on the CKD-EPI (Chronic Kidney Disease Epidemiology 
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Collaboration [8]) or the MDRD (Modification of Diet in Renal Disease [9]) study equation. 
Both equations are considering the same four variables age, gender, race and serum creatinine 
concentration. Compared to the gold standard GFR measurement using radioactive 
125
I-
iothalamate the CKD-EPI equation gives the most accurate estimation for GFR greater than 
60 milliliters per minute, but the MDRD study equation is still used in 92% of US laboratories 
as its accuracy is close to that of the CKD-EPI [10]. 
 
 
 
 
 
Figure 1: Prognosis of CKD by GFR and albuminuria 
Risk for prognosis of CKD and end-stage renal disease (ESRD) is predicted by GFR category ranging from 
normal (eGFR > 90 ml/min, G1) to kidney failure (eGFR < 15 ml/min, G5) and by severity of albuminuria (A1 
to A3).  
Green: low risk; yellow: moderately increased risk; orange: high risk; red: very high risk. Taken and adapted 
from KDIGO 2012 – Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney 
Disease, Levin A. et al., Kidney Int 2014 [11]. 
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Chronic kidney disease (CKD) is defined as either kidney damage or a glomerular filtration 
rate (GFR) below 90 milliliters per minute for more than three months [12]. Kidney damage 
includes structural alterations and abnormalities in blood or urine e.g. hematuria and 
proteinuria [13]. Proteinuria, the loss of protein into the urine, is the most common marker of 
kidney damage indicating glomerular damage. The main protein in human blood plasma is 
albumin.  
 
CKD is currently categorized in specific stages based on the presence of albuminuria (A) and 
the reduction of GFR (G) (see Figure 1) [11, 12]. In stages G1 and G2 GFR may be normal or 
mildly decreased. Additional pathological changes such as glomerular and interstitial fibrosis 
or tubular atrophy appear beside the decreased GFR in stages G3 to G4 [14]. According to 
this classification system, dialysis patients with end-stage renal disease (ESRD) are diagnosed 
as CKD stage G5. With the latest KDIGO classification albuminuria is integrated in the CKD 
classification, categorizing albuminuria (A) into grades 1 to 3. For instance, individuals with 
normal GFR (category G1) but with severe albuminuria (category A3) are referred to the 
category of high risk for cardiovascular diseases and ESRD (see Figure 1) as albuminuria has 
been proven to be a crucial contributor to renal disease. 
Signs and symptoms of CKD may include edema, especially the swelling of the legs and eye 
puffiness due to fluid retention, high blood pressure and fatigue. Also anemia, shortness of 
breath from fluid accumulation in the lungs or metabolic acidosis, loss of appetite and bone 
disease occur [14, 15].  
CKD can be caused by a variety of clinical factors including toxins, autoimmune diseases and 
glomerulopathies, infections, abnormalities of the urinary tract and genetic alterations but the 
major causes are diabetes mellitus and hypertension [16, 17]. Diabetes can harm the kidneys 
by causing damage to the glomerular capillaries leading to diabetic kidney disease [18], 
whereby in the advanced stage of diabetic kidney disease (DKD), proteinuria and diffuse 
glomerulosclerosis is observed [19]. Furthermore, increasing of individuals with obesity 
(body-mass index higher than 25 and waist circumference more than 102 cm for men and 
more than 88 cm for women) and the growing aging population are further risk factors that 
can explain the increasing prevalence of CKD [12, 20, 21]. The progression of renal disease 
occurs with advancing age as a natural loss of renal mass starts with the age of 40 years by 
reducing the glomeruli about 10% in each ten years [22].   
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CKD was extensively studied in rodents in the remnant kidney model with 5/6 nephrectomy 
[23, 24]. This nephrectomy model results in progressive hyperperfusion, hyperfiltration, 
hypertrophy and glomerulosclerosis. Glomerular hyperfiltration, one of the key processes in 
progressive renal injury, showed in a recent study with renal biopsies from patients diagnosed 
with diabetic kidney disease, a close association with increased glomerular filtration surface 
[25]. This may explain the initial increased GFR in these patients although urinary albumin 
level is elevated.  
 
In the last decade, several studies on genomic and transcriptomic level identified new factors 
that are involved in CKD [26-34]. In a genome-wide association study (GWAS) 
polymorphisms in MYH9 and APOL1 were associated with nondiabetic ESRD in African-
Americans [30, 31]. Variants in MYH9 and APOL1 have been identified as risk variants for 
developing progressive CKD in individuals with African descent. The CKDGen consortium 
performed a meta-analysis of GWAS data from Caucasian patients and found 13 novel loci 
(e.g. SLC7A9, SLC34A1, DAB2) associated with kidney function, the GFR, and CKD. Single 
nucleotide polymorphisms (SNPs) at these loci may have influence on the renal function [35]. 
Mutations in the UMOD gene are allied with decline in renal function and cause the 
autosomal dominant tubulointerstitial kidney disease [36-38]. A further study based on the 
data from the CKDGen consortium and the CARe consortium, identified CUBN as a gene 
locus for microalbuminuria in Caucasians as well African Americans irrespective of 
associated disorders such as diabetes [39].  
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1.1. Early intervention and therapeutic approaches 
Medical treatment of CKD and CKD-related diseases causes one fifth of the entire annual 
medicare costs in the United States and the expenses are rising continually [16, 40-44]. 
Patients with CKD are at an increased risk not only for end-stage renal disease (ESRD), but 
also for cardiovascular disease (CVD) (Framingham Heart Study) [13, 45]. In the earlier 
stages of CKD (2 to 3) statin therapy showed to lower low-density lipoprotein (LDL) 
cholesterol levels and consequently reduced cardiovascular events in these patients [46]. 
 
Several studies showed that proteinuric patients have an increased risk of progressive renal 
failure compared to non-proteinuric CKD patients and that progression rate correlates with the 
degree of residual proteinuria [47-49]. The administration of drugs such as angiotensin 
converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) allow control 
of blood pressure and proteinuria in CKD patients [50, 51]. The reduction in proteinuria in the 
first months of treatment with drugs that inhibit the renin-angiotensin-aldosterone system 
(RAAS) is associated with long-term kidney function protection, independently from the 
effect of the antihypertensive drug [52-55]. The ONTARGET study (Ongoing Telmisartan 
Alone and in Combination with Ramipril Global Endpoint Trial), a multicenter randomized 
controlled trial, examined the impact of combined administration of angiotensin receptor 
blockers (ARB) and angiotensin converting enzyme inhibitors (ACEi) in hypertensive 
patients with established atherosclerotic vascular disease [51]. Both the combined and the 
solely administration reduced hypertension and proteinuria equally well, but in the combined 
administration more adverse side-effects such as hyperkalemia were observed and long-term 
use indicated to worse renal function [51, 56-58].   
 
A five-year period study with normotensive and normoalbuminuria patients with type 1 
diabetes, showed that early blockade of the renin-angiotensin system did not prevent 
nephropathy progression [55]. As cardiovascular disease is one of the leading causes for 
morbidity and mortality in CKD patients, early intervention with low-salt and low-fat diet, 
blood pressure control and smoking cessation is recommended [59, 60]. 
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Further, metabolic bone disease is a common complication of chronic kidney disease (CKD) 
in the progressed stages 4 to 5. It is caused by disturbance of bone and mineral metabolism in 
consequence of hyperphosphatemia, hypocalcemia and decreased levels of active vitamin D 
[14, 61]. The abnormalities in bone morphology is leading to higher incidences of fractures, 
and hyperphosphatemia has been found to be a mortality risk factor in patients with CKD 
[62]. In these patients very high levels of fibroblast growth factor 23 (FGF-23) and 
parathyroid hormone (PTH) are measured [63, 64]. Faul et al. demonstrated in a large cohort 
of CKD patients that circulating FGF-23 is highly associated with left ventricular hypertrophy 
(LVH) and risk for mortality [65]. 
Recent studies have indicated that renal klotho expression is markedly suppressed in CKD in 
mice and humans suggesting that decreased klotho expression may also be involved in the 
pathophysiology of CKD [66]. The klotho gene (KL) is predominantly expressed in kidney, 
where it functions as a co-receptor for FGF-23. FGF-23 is a bone-derived hormone that 
suppresses phosphate reabsorption and 1,25-dihydroxyvitamin D3 (vitamin D) synthesis in the 
kidney and decreases expression and secretion of PTH. Mice lacking either FGF-23 or klotho 
exhibit hyperphosphatemia [67]. These findings correspond to human studies whereby 
decrease of urinary klotho protein levels was observed in patients with early stage CKD (stage 
1 and 2) suggesting urinary klotho as an early biomarker of progression [68, 69]. 
 
Chronic kidney disease (CKD) is a worldwide public health problem with an increasing 
incidence and prevalence with various implications (see above) [44]. Earlier detection and 
suitable treatment is essential for slowing the progression of CKD.  
As a consequence, three parameters should be screened for kidney disease: blood pressure, 
protein or albumin in the urine and glomerular filtration rate (GFR). 
 14 
2. PROGRESSION OF CHRONIC KIDNEY DISEASE 
Chronic kidney disease affects more than 13% of the population in the United States as well 
as in Europe and a certain proportion of cases progress to end-stage kidney failure [16, 42]. 
Progression of renal disease is characterized, apart from decline of GFR, by 
glomerulosclerosis, interstitial leukocyte infiltration, tubular atrophy, and tubulointerstitial 
fibrosis [70-73]. Thus, involvement of both, the glomeruli and the tubulointerstitium, 
contributes to progression of renal disease.  
Halbesma et al. performed a study to develop and validate a “Renal Risk Score” for the 
general population [74]. The prediction model contained eGFR, age, urinary albumin 
excretion, systolic blood pressure and known hypertension. In this study, the first sign of 
kidney damage is decline of eGFR. Renal dysfunction characterized by a progressive decline 
of the glomerular filtration rate (GFR < 60 ml per minute) is often accompanied by 
proteinuria, the loss of protein in the urine (Figure 1).  
As previously mentioned, other risk factors for CKD progression are high blood pressure 
(>130/80 mmHg), hyperglycemia (diabetes mellitus), obesity, dyslipidemia and tobacco use 
[75, 76]. Hallan et al. identified in an epidemical study, the combination of reduced eGFR and 
albuminuria or proteinuria as a powerful predictor of progression to ESRD [77]. 
The activation of the renin angiotensin aldosterone system (RAAS) also contributes to 
glomerular and tubulointerstitial remodeling and injury, in part through generation of reactive 
oxygen species [78]. Numerous cytokines and growth factors appear to modulate progression 
of glomerular and tubulointerstitial scarring since altered gene expression has been found in 
progressive renal scarring (e.g. PAI-1; PPAR-γ; PDGF; TGF-β; Ang II) [79-83].  
 
Progression factors can be distinguished in clinical and histological factors: 
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2.1. Clinical factors 
2.1.1. Proteinuria 
The presence of proteinuria is associated with an increased risk for CKD and cardiovascular 
disease, as shown by many studies [15, 75, 84]. High proteinuria is defined as urinary protein 
excretion of greater than 3.5 grams per day and is one symptom of the nephrotic syndrome 
[85]. Independently of the underlying causes, chronic proteinuric glomerulopathies have in 
common the loss of selectivity of the glomerular barrier. Proteins with a molecular weight 
below 60 kDa usually pass freely through the glomerular basement membrane and are 
actively reabsorbed within the tubular system [86]. The severity of proteinuria depends on the 
damage of the glomerular capillary wall and the intraglomerular pressure. The intraglomerular 
pressure is controlled by the afferent and efferent arterioles and may be normalized by 
reduction of the systemic blood pressure. A blood pressure less than 130/80 mmHg is 
recommended for a better clinical outcome of CKD with high proteinuria [12]. 
 
Proteinuria is not only a strong marker for renal outcome, but also a marker for increased 
cardiovascular risk [86-88]. Urinary proteins themselves may induce proinflammatory and 
profibrotic effects that directly contribute to chronic tubulointerstitial damage. Induction of 
tubular chemokine expression and complement activation lead to inflammatory cell 
infiltration in the interstitium and persistent fibrogenesis [18]. In animal models, overload 
albumin (protein) causes interstitial inflammation and fibrosis, and induces expression of a 
number of inflammatory and fibrogenic mediators such as RANTES, monocyte chemotactic 
protein 1 and interleukins [89, 90]. 
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2.1.2. Other clinical factors 
Other contributors to progression are high glucose (diagnosed diabetes), hypertension and 
nephrotoxic drugs (e.g. cyclosporine) such as non-steroidal anti-inflammatory drugs 
(NSAIDs) [91-93]. In diabetes, decreased insulin sensitivity and hyperinsulinemia, in 
conjunction with hypertension, contribute to glomerular mesangial expansion, podocyte 
remodeling, loss of slit pore diaphragm integrity, and basement membrane thickening. 
Therefore, control of blood pressure and diabetes is an important key in treatment of CKD. 
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2.2. Histological factors 
Involvement of both, the glomeruli and the tubulointerstitium, contributes to progression of 
renal disease as observed in kidney biopsies taken from patients with CKD [71]. 
Many cellular and molecular events beyond the production of matrix components promote the 
progression of fibrotic injury, and are actually responsible for the progressive loss of kidney 
function [94]. In patients with CKD, the histopathological presentation of tubular damage is 
often characterized as tubular injury and atrophy. 
In the glomerulus, matrix accumulation, proliferation or loss of mesangial and endothelial 
cells, and the alteration and loss of functional podocytes are observed [71]. Therefore, all 
three glomerular cell types, the endothelial cells, mesangial cells and podocytes, are 
contributing to the fibrotic process. 
 
 
2.2.1. Renal fibrosis 
Renal fibrosis, characterized by glomerulosclerosis and tubulointerstitial fibrosis, is the final 
common manifestation of chronic kidney disease (CKD) [19]. The pathogenesis of renal 
fibrosis is a progressive process which leads to end-stage renal failure. Many cellular and 
molecular events, such as tubular atrophy, vascular rarefaction and hypoxia, promote the 
progressive loss of kidney function and determine the outcome of renal fibrosis. The loss of 
podocytes is considered as a major determinant and prognostic indicator for glomerular 
sclerosis [70].  
 
It is generally accepted that activated fibroblasts (myofibroblast-phenotype) are responsible 
for excessive extracellular matrix (ECM; type I and III collagen, fibronectin) deposition 
leading to interstitial fibrosis [79, 95-97]. These alpha smooth muscle actin (α-SMA) 
expressing cells are recognized as a predictor of fibrotic progression in renal disease [98]. 
Type I collagen, one of the major fibrillar collagens, is involved in fibrosis but the 
mechanisms of transcriptional activation of the gene in kidneys remain unclear [99, 100]. A 
further central mediator, transforming growth factor beta (TGF-β), up-regulates many 
fibrogenic factors positively such as connective tissue growth factor by Smad2 or Smad3 
molecules [17, 101, 102]. In-vitro studies with human fibroblasts showed that TGF-β induces 
α-SMA and actin-associated proteins that are participating in the formation of stress fibers, 
cell contractility and spreading [103, 104]. Overexpression of active TGF-β1 in mice causes 
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mesangial expansion, interstitial fibrosis, decreased GFR and progressive proteinuria [105]. 
However, therapies that target TGF-β are still non-effective and have very limited effects on 
renal fibrosis [106]. In an early TGF-β-independent Smad pathway, the renin-angiotensin 
system is involved in the development of vascular sclerosis by activating Smad3 through 
Angiotensin II (Ang II) [107, 108].  
 
A further relevant contributor to kidney fibrosis progression appears to be hypoxia. Hypoxia 
leads to tubulointerstitial ischemic damage, which results in the loss of peritubular capillaries 
[109, 110]. Activation of the hypoxia-inducible factor (HIF) pathway by induction of vascular 
endothelial growth factor (VEGF) or stabilization of HIF proteins promotes renal fibrosis 
[111-115]. 
An innovative approach to identify progression factors was developed by Ju et al. [33]. There, 
intrarenal mRNA expression signatures predicted progressive renal fibrosis in mice and could 
be transferred to data from humans with CKD. 
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2.3. End-stage renal disease and renal replacement therapy 
End-stage renal disease (ESRD) is defined as advanced chronic kidney disease. According to 
the classification system of KDIGO, dialysis patients with ESRD are diagnosed as CKD stage 
5 [11]. Uremia is one main clinical symptom that occurs in patients with chronic renal failure. 
ESRD with uremic syndrome is characterized by impairment of acid-base and hormone 
metabolism, which results in disturbance of blood pressure and degradation of metabolism 
products such as urea and creatinine. Symptoms are uremic odor of breath and skin (uremic 
fetor), pruritus and discoloration of skin tone. Further implications of renal failure include 
edema, hypertension, cardiac arrhythmias, renal anemia, renal osteopathy and myopathy 
[116]. Renal replacement therapy is needed in these patients [117]. In 2006, the NKF 
workgroup updated the guidelines for initiating dialysis at the estimated glomerular filtration 
rate (eGFR) below 15 mL/min/1.73 m
2
. According to the IDEAL study, early initiation of 
dialysis in patients with stage 5 CKD had no benefit on clinical outcome or survival 
prolongation [118, 119]. In the United States, approximately 40% of patients starting dialysis 
had diabetic kidney disease [40]. 
 
 
2.3.1. Hemodialysis 
Hemodialysis (HD) prolongs life for patients with ESRD by restoring the intracellular and 
extracellular fluid balance, electrolyte homeostasis and acid-base equilibrium. This is 
obtained by the diffusion of molecules in solution across a semipermeable membrane along 
an electrochemical concentration gradient. Uremic toxins are eliminated from the blood and 
transported into the dialysate and important solutes such as bicarbonate are returned into the 
blood. Complications and side effects of HD include hypotension, muscle cramps, and 
advanced atherosclerosis. Most symptoms associated with the uremic syndrome are 
eliminated but it is not possible to replace the kidney function entirely [120, 121]. Longer 
session lengths and more frequent hemodialysis proved to be beneficial for phosphorus serum 
levels and therefore could prevent the typical bone disorder caused mainly by 
hypophosphatemia in these patients [122]. 
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2.3.2. Peritoneal dialysis 
Peritoneal dialysis (PD), an alternative therapy to hemodialysis (HD), is used by more than 
272,000 patients with ESRD worldwide [123], accounting for approximately 11% of the 
dialysis population [124]. Concerns about patient survival on HD in comparison with PD may 
have led nephrologists to select this type of dialysis for their patients [125-127]. A 
prospective study with HD and PD patients showed that residual GFR is better maintained in 
PD patients [128]. 
PD involves the exchange of solutes and fluid between the peritoneal capillaries and the 
intraperitoneal dialysis solution across the peritoneal membrane. It requires placement of a 
peritoneal dialysis catheter for repeated dialysate exchange. The development of alterations in 
the peritoneal membrane, peritoneal sclerosis and fibrosis, is a major chronic complication of 
PD treatment. These alterations are characterized by vascular changes (increased number of 
vessels) and by thickening of the submesothelial zone (fibrotic altering) [129, 130]. The cause 
of peritoneal fibrosis is not clear, but human and murine studies suggested that mainly uremia 
induces fibrotic changes in the peritoneum [131, 132]. Furthermore, the bio-incompatible 
peritoneal dialysis solutions composed of glucose, glucose degradation products or/and 
advanced glycation end products and the acidic pH promote chronic inflammation and fibrotic 
altering [133].  
A rare complication of long-term peritoneal dialysis is encapsulating peritoneal sclerosis 
(EPS) [131, 134]. Formation of a fibrous cocoon encapsulating the bowel leads to acute 
gastrointestinal obstruction. The mortality in patients with EPS is high (25-50%) and no 
established treatment is available. 
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2.3.3. Renal transplantation 
Kidney transplantation is the third and for several reasons preferable renal replacement 
therapy. The majority of renal transplant recipients are already on dialysis at the time of 
transplantation [135]. Although life-long immunosuppressive therapy is needed to prevent 
allograft rejection, renal transplantation represents the best option for most patients with 
ESRD with respect to survival, quality of life and control of whole body homeostasis. In the 
last decades, progress in renal transplantation was achieved and organ survival rate has 
improved remarkably.  
 
Ongoing studies are searching for clinical and histological markers to predict the outcome of 
transplantation [136]. Beside immunological factors the GFR, fibrotic lesions and age of 
allograft recipient and donor seem to be important. Strikingly, 50% of allograft loss cases are 
due to death of the recipient mainly caused by associated disorders [137, 138]. Clinically, 
renal allograft biopsies are evaluated by the Banff classification which defines five categories 
of renal transplantation pathology [139]. The purpose is to detect first signs of renal 
dysfunction and therefore to prevent transplant rejection.   
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3. GLOMERULONEPHROPATHIES 
Current data from the United States and Europe indicate that diabetes mellitus (primarily type 
2), hypertension and glomerulonephritis are major causes for the development and 
progression of renal diseases [40]. In all three entities the glomerulus, the filter unit of the 
kidney, is primarily affected. The glomerulus consists of three layers: the fenestrated 
endothelium and glycocalyx, the specific glomerular basement membrane and the glomerular 
epithelial cells, also called podocytes (Figure 2). The latter play an important role in the 
selective permeability of the filter barrier as these cells with their interdigitating foot 
processes, form the slit diaphragm. One common clinical finding due to dysfunction of this 
construct in progressive kidney diseases is proteinuria, the excessive loss of protein with the 
urine [140-143]. As mentioned previously, podocyte dysfunction may be caused by genetic 
and/or environmental factors (e.g. diabetes, hypertension or aging) [144]. 
Glomerular diseases account for up to 60% for end-stage renal disease (ESRD) in the 
industrialized world [40]. The signs and symptoms of glomerular disease include: reduced 
glomerular filtration rate (GFR), proteinuria and/or hematuria. Clinically, these 
pathophysiological features are distinguished into two main syndromes. The nephrotic 
syndrome is characterized by massive proteinuria (more than 3 grams per day) and edema, 
whereas the nephritic syndrome is accompanied by leukocytic infiltration and inflammation 
of the capillaries leading to hematuria, the loss of erythrocytes in the urine. Glomerular 
diseases with nephrotic syndrome can be divided into primary and secondary etiologies. 
Primary caused glomerulonephropathies (GNs) have an acute onset as symptoms such as 
proteinuria with or without nephrotic syndrome occur in a previously healthy person. 
Idiopathic, primary GNs with a nephrotic syndrome include minimal change disease (MCD), 
focal-segmental glomerulosclerosis (FSGS) and membranous glomerulonephropathy (MGN). 
Secondary caused GNs are associated with certain infections (e.g. HIV/AIDS, hepatitis B and 
C), drugs (cyclosporine A, non-steroidal anti-inflammatory drugs (NSAIDs)), systemic 
disorders (e.g. systemic lupus erythematosus (SLE)) or diabetes mellitus. Several hereditary 
disorders may be associated with genes with prominent glomerular relevance such as Alport’s 
syndrome or Nail-Patella syndrome (mutations in COL4A5 and LMX1B, respectively) and 
direct podocyte biology (see below).  
Furthermore, chronic glomerulonephropathies (GNs) are classified into non-proliferative and 
proliferative types. The proliferative type is characterized by an increased number of 
glomerular cells, especially the mesangial cells, and usually leads to nephritic syndrome. IgA 
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nephropathy (Berger’s disease) is the most common type of a proliferative GN in adults 
worldwide [140, 145].   
 
 
3.1. Main acquired proteinuric glomerulonephropathies 
There are three main causes for primary idiopathic nephrotic syndrome, minimal change 
disease (MCD), focal-segmental glomerulosclerosis (FSGS) and membranous 
glomerulonephropathy (MGN) (Figure 2) [143].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Acquired proteinuric glomerulonephropathies 
The main proteinuric glomerular diseases are focal-segmental glomerulosclerosis (FSGS), membranous 
glomerulonephropathy (MGN) and minimal change disease (MCD). The renal filtration barrier consists of three 
layers, the glomerular fenestrated endothelial cells, the negatively charged glomerular basement membrane 
(GMB) and podocytes with their foot processes. One common finding is the loss of the functional podocytes, 
which leads to alterations of the permselectivity barrier of the glomerular capillary wall, allowing increasing 
loss of plasma proteins into the urine. Taken and adapted from Primer on Kidney Diseases, Greenberg et al., 
National Kidney Foundation 2009. 
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These GNs have no increase in number of cells, and are therefore grouped into the non-
proliferative type. These renal diseases show one common pathological finding: the loss of 
the highly differentiated phenotype of podocytes, which are required for the function of the 
filter barrier.  
 
The progressive renal diseases such as FSGS and MGN have a high risk of ESRD whereas 
MCD reveals a good remission opportunity with immunosuppressive treatments such as 
steroid therapy (corticosteroids) with no loss of GFR. Steroid-sensitive GNs may be identified 
on renal biopsy with only minimal changes without immunoglobulin deposits.  
Although treatments with steroids, calcineurin inhibitors, cyclophosphamide (CYC) and 
rituximab (RTX) are efficient in the majority of cases, certain patients are non-responders due 
to genetic alterations (e.g. steroid-resistant GNs). GNs caused by genetic abnormalities are 
predominantly associated with mutations in podocyte genes (e.g. nephrin (NPHS1), podocin 
(NPHS2), α-actinin-4 (ACTN4), phospholipase C epsilon 1 gene (PLCE1), Wilms tumor 
suppressor gene (WT1), TRPC6) [146-151].  
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3.1.1. Minimal change disease (MCD) 
This form of glomerulonephropathy causes 80% of nephrotic syndrome (NS) in children, but 
only 20% in adults. In clinical practice, about 95% of MCD patients respond to 
immunosuppressive therapy such as corticosteroids, alkylating agents (e.g. 
cyclophosphamide), calcineurin inhibitors (e.g. cyclosporine or tacrolimus) or monoclonal 
antibody rituximab. On electron microscopy, a “fusion” of podocyte foot processes is visible 
only as apparent histological abnormality (Figure 2). Despite significant progress in 
understanding the kidney ultrafiltration barrier, the molecular mechanism remains unclear. 
Earlier studies showed an association with personal or familial history of atopy [152]. 
However, this podocyte injury in MCD is reversible, so that progressive loss of renal function 
is rare. The absence of any glomerular abnormality on light microscopy and the complete 
remission of proteinuria on corticosteroid treatment easily distinguished MCD from FSGS 
[153]. 
 
Animal models of MCD are induced with puromycin aminonucleoside (PAN) low-dose 
injections, which are leading to proteinuria, foot process effacement and responsiveness to 
steroids [154, 155]. Garin et al. showed that the expression of podocyte-specific B7-1 was 
highly present in the urine of MCD patient but not in those with idiopathic FSGS and 
therefore suggesting urinary B7-1 as a specific marker for MCD [156].  
In 2010, the abundance of c-maf inducing protein (c-mip) in podocytes of patients with MCD 
was reported. Transgenic mice overexpressing c-mip in podocytes developed proteinuria 
without morphological alterations, inflammatory lesions or cell infiltration [157]. In a recent 
study, a role of angiopoietin-like-4 (ANGPTL4) in glucocorticoid-sensitive nephrotic 
syndrome was identified [158]. Up-regulated expression of ANGPTL4 was found in the 
serum and in podocytes in experimental rodent models of MCD. Sera from human patients 
with MCD confirmed the result. Rats overexpressing ANGPTL4 in podocytes develop 
albuminuria, loss of specificity of the glomerular basement membrane (GBM) as well as 
podocytes foot processes effacement, supposing a causative role of ANGPTL4 in MCD. 
Clement et al. suggest that ANGPTL4 in MCD might represent a podocytes-derived factor 
that may act in an autocrine or paracrine manner [158].  
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3.1.2. Focal-segmental glomerulosclerosis (FSGS) 
In FSGS, beside foot process effacement as in MCD, certain foci of glomeruli within the 
kidney are affected by lesions such as sclerosis and hyalinization of the arterioles. In the 
affected segments hyaline deposition around the shrinking capillary loops and increased 
mesangial fibrillar material without any cellular proliferation is found. While the majority of 
MCD patients respond to steroid therapy, most of FSGS patients are resistant to 
corticosteroids. Compared with MCD, idiopathic FSGS is associated with steroid resistance 
and higher risk of progression for renal failure. Originally, the histological diagnosis of FSGS 
required the identification of segmental sclerotic lesions in at least one glomerulus [159, 160]. 
FSGS is one of the leading causes for ESRD, especially in African-Americans and Hispanics 
[161]. In African-Americans, genetic variants in the MYH9 and APOL1 locus have been 
associated with high risk for progression of FSGS and its outcome [30, 31].  
 
FSGS may be a primary idiopathic or secondary GN caused by drug abuse or HIV infection. 
Hereditary FSGS is caused by mutations in podocyte genes such as nephrin (NPHS1) or 
podocin (NPHS2) responsible for the Finish-type congenital nephrotic syndrome and 
autosomal recessive familial FSGS, respectively. Autosomal dominant FSGS with adult onset 
is caused by a mutation in α-actinin 4 (ACTN4) leading to altered actin-cytoskeleton 
interaction [162]. It has also been hypothesized that circulating factors in plasma are causing 
FSGS, as there is a significantly high risk of recurrence of FSGS in renal transplants observed 
[163, 164]. In 2011, a study of the group of Jochen Reiser identified serum soluble urokinase 
receptor (suPAR) as a potential circulating causative factor that is elevated in the serum of 
approximately two-thirds of primary FSGS patients, but not in patients with other glomerular 
diseases [165]. Circulating suPAR activates β3 integrin (ITGB3) in podocytes, which has 
been shown to be involved in podocytes foot process effacement. 
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3.1.3. Membranous glomerulonephropathy (MGN) 
MGN is the most common cause for nephrotic syndrome in adults. Microscopically, MGN is 
characterized by a thickened glomerular basement membrane (GBM) with formation of 
subepithelial immune deposits within which results in dysfunction of the glomerulus and 
causing massive proteinuria. The involved immune complexes consist of IgG4 and other 
antigens [166]. In earlier studies in a rat model of MGN (Heymann’s nephritis), antibodies 
directed against megalin were discovered [167]. However, megalin is not expressed in human 
podocytes. Debiec et al. characterized a fetomaternal disease in which antibodies to neutral 
endopeptidase (NEP) caused the development of MGN in fetus of NEP deficient mothers [29, 
168]. Therefore, NEP deficiency should also be considered in patients developing de-novo 
MGN after renal transplantation.  
In 2009, the anti-phospholipase A2 receptor (PLA2R) was identified as a major target 
autoantigen in adult idiopathic MGN [28, 169, 170]. Circulating anti-PLA2R IgG4 were 
found in sera from 70% of patients with primary idiopathic MGN but not in those with 
secondary MGN or other GNs. Immunofluorescence staining localized PLA2R in normal 
human podocytes, which was further confirmed by positive staining with Wilms Tumor 1 
(WT1). Currently, the anti-B cell agent rituximab is one of the promising therapy options for 
idiopathic MGN. In a cohort study, rituximab treatment correlated with a decline of anti-
PLA2R autoantibodies in MGN patients with a complete or partial remission. Low anti-
PLA2R autoantibody titers might represent a potential biomarker for positive treatment 
response [169, 171, 172]. 
Furthermore, two autoantibodies against aldose reductase (AR) and mitochondrial superoxide 
dismutase 2 (SOD2) were discovered to be present in serum and glomeruli from patients with 
MGN [27]. Recently performed genome-wide association studies of single-nucleotide 
polymorphisms (GWAS) in patients from Caucasian ancestry with idiopathic MGN identified 
coding and non-coding regions of HLA-DQA1 and PLA2R1 as risk alleles. PLA2R1 is 
present in normal podocytes and in immune deposits in patients with idiopathic MGN [26, 
173]. All these findings support the concept of circulating autoantibodies binding to 
glomerular antigens expressed on podocytes and may explain the onset of MGN.  
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4. EUROPEAN RENAL cDNA BANK-KRÖNER-FRESENIUS BIOPSY 
BANK 
Towards the end of the 20th century, experimental models and gene expression analysis have 
become evermore an important research tool in renal research as several genes have been 
identified with key relevance for renal function [36, 112, 174-177]. The renal biopsy and the 
succeeding histological examination are routine clinical and diagnostic gold standard in 
nephrology. In nephrology, research methods such as immunohistochemistry, light and 
electron microscopy are well established, but gene expression analysis will provide an 
improvement in routine diagnostic information regarding diagnosis, treatment response and 
prognosis of disease progression. 
 
Hence, in 1998, an international multicenter study, the European Renal cDNA Bank-Kröner-
Fresenius Biopsy Bank (ERCB-KFB) was initiated to enable the systematic analysis of gene 
expression in human kidney biopsies. The objectives were defined as follows:  
1.) Improving understanding of transcriptional mechanisms involved in human renal disease, 
2.) Identifying diagnostic and prognostic markers in renal biopsies, and 3.) Supporting the 
renal scientific community by translational research [178]. 
Nevertheless, a kidney biopsy is still an invasive procedure despite considerable 
developments in recent years. The development of highly sensitive detection methods is 
therefore required for the molecular analysis of multiple RNAs from small amounts of tissue 
(see standardized protocol) [179]. Two methods have been established in recent years to 
investigate which genes are transcribed in a tissue: Quantitative real-time RT (reverse 
transcriptase)-PCR (polymerase chain reaction) and microarrays. The first method is very 
sensitive, even the smallest amounts by amplification of a specific nucleic acid sequence can 
be quantified [180]. Microarrays allow simultaneous analysis of thousands of cDNAs [181]. 
Including clinical data in the further parallel analysis (e.g. laboratory values, histology) at 
time of biopsy and at subsequent dates, it may be possible to correlate the expression pattern 
of certain genes with clinical outcome or response to therapy (Figure 3) [178, 182].  
In particular, gene expression studies based on renal biopsies have made an important 
contribution to understanding the role of transcriptional regulation in renal disease [176, 183, 
184]. With the variety of data from animal models, it is increasingly important to verify the 
results with respect to their applicability to humans. Often this is done by morphological 
methods such as histology and immunohistochemistry [185]. The ERCB-KFB offers the 
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possibility of comparison to another level. By this time more than forty international clinical 
centers are part of this comprehensive study and over 2900 renal biopsies have been collected. 
Since its initiation several publications in respectable journals have been emerged from and 
high reproducibility has been confirmed [110, 176, 178, 182, 184, 186, 187].  
 
 
 
 
Figure 3: Outline of the European Renal cDNA Bank-Kröner-Fresenius Biopsy Bank (ERCB-KFB) 
Immediately after renal biopsy, a minimum of 10% of the biopsy specimen is separated and stored in RNA 
preservative. Under a stereomicroscope, glomeruli and tubulointerstitial compartments are divided by manual 
microdissection. The gene expression analysis is performed by real-time   RT-PCR   or   microarrays. Clinical 
characteristics of the patients are collected in parallel to enable integrative analysis of the gene expression data 
[182]. 
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To cite as an example, the working group of Susan Quaggin examined a mouse model of  
rapidly-progressive glomerulonephritis (RPGN) with glomerular deletion of Von Hippel-
Lindau gene (Vhlh) and noted the induction of hypoxia-associated cellular processes such as 
necrotizing glomerular crescents [188]. The investigation of RPGN patients with 
microdissected glomeruli from the ERCB-KFB yielded the same gene expression pattern as in 
animal models. Although the pathogenic mechanism of RPGN in humans remains unclear, 
from these findings may result new therapeutic approaches for blocking the specific hypoxia-
induced gene Cxcr4 by extending the survival of mice knowing that hypoxia is a key 
mechanism in the pathogenesis of renal disease. The finding that hypoxia is a central 
mechanism in the pathogenesis of kidney disease, was also approved from the work of 
Higgins et al. where the expression of hypoxia-induced renal factor HIF-1α enhances renal 
fibrosis in mice [113]. Once more using data from the ERCB-KFB has been shown that this 
pathomechanism seems to be applicable for humans. Thus, the main goals of the ERCB-KFB 
are both, generating hypotheses on the nature of kidney diseases and translating results from 
animal models to humans, and to identify pathophysiological processes in human renal 
diseases for a better clinical outcome. This approach might reveal new findings on molecular 
level, which can be made in clinical knowledge.   
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5. PURPOSE AND PREFACE 
In the last two decades, several studies brought a lot for the understanding of the mechanisms 
involved in CKD development. However, most data still come from animal models and 
translation to human CKD is often not given. The initial aim of this PhD project was to 
identify gene transcripts involved in human CKD by analyzing gene expression profiles based 
on samples of the ERCB-KFB using most recent technical and bioinformatical tools (e.g. 
Bibliosphere, DAVID, Ingenuity etc.). The fact that not only the GFR, but also proteinuria 
has essential influence on the progression of CKD, prompted us to mainly focus on 
proteinuria in acquired proteinuric glomerulopathies, namely MCD, FSGS and MGN (see 3.). 
A systematic analysis of the molecular mechanisms involved in glomerular proteinuria is 
necessary to comprehend the biological processes behind: 
 
For that purpose, a human renal glomerulus-enriched gene expression dataset, REGGED, was 
generated to filter for glomerular gene transcripts of interest. REGGED implicates the most 
known glomerular markers compared to other published reports on human glomerular 
expression at the time of publication, which confirms the high validity and excellent quality 
of this database [174, 189-191]. The chapter I shows the published results from this 
international collaboration study including in-vitro validation experiments.  
Chronic hypoxia contributes to renal fibrosis associated with preceding microvasculature 
dysfunction in several rodent studies and was hypothesized to be involved in nephrosclerosis 
(NSC), also known as hypertensive nephropathy [192, 193]. In chapter II, we performed 
specific studies to comprehend the biological processes of hypoxia-related renal injury. We 
found induced glomerular expression of genes regulated by the hypoxia-inducible factors 
(HIFs) in NSC such as the chemokine C-X-C motif receptor 4 (CXCR4). In NSC biopsies, 
CXCR4 showed an enhanced expression in podocytes with an associated nuclear positivity of 
the hypoxia-inducible factor-1α (HIF1α) suggesting a transcriptional activity of HIF1α.  
 
In a further step, our REGGED dataset was used to select a glomerular gene transcript with a 
high induction in progressive proteinuric glomerulopathies such as FSGS and MGN. 
Matricellular proteins such as SPARC are known to contribute to the progression of human 
nephropathies [194, 195]. To achieve a better comprehension for the pathobiology of 
progressive proteinuric diseases, a systematic analysis of the matricellular protein POSTN 
(Periostin) was conducted. POSTN (Periostin), also known as osteoblast-specific factor 2 
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(OSF-2) was systematically analyzed and found to be expressed in healthy glomeruli with the 
highest induction in the progressive diseases FSGS and MGN. In the chapters III and IV, 
studies on POSTN and fibrosis/fibrotic alterations, a hallmark of renal disease progression, 
were performed by using different methodical approaches. In chapter III renal biopsies taken 
from patients with proteinuric glomerulopathies in various phases of disease progression were 
analyzed, compared to clinical data and confirmed by in-vitro experiments. As expected, 
POSTN was strongly associated with the progression of proteinuric diseases. The chapter IV 
continued the experiments with biopsies and clinical data from patients on peritoneal dialysis 
(PD) with or without developed encapsulating peritoneal sclerosis (EPS). Periostin 
concentrations in dialysate of PD patients without signs of EPS significantly increased with 
time of treatment. The chapter V contains functional studies on POSTN including ex-vivo 
examinations of a periostin-deficient mouse. The kidneys of periostin-deficient mice showed 
enlarged glomeruli and a proliferative mesangium suggesting worse renal function. This was 
confirmed by measuring the serum data such as the blood urea nitrogen level. 
 
Patients with primary podocyte-injured renal diseases such as MCD are treated with 
glucocorticoids and a part of them respond rapidly with improvement of proteinuria or even 
full remission. The detection of REGGED gene transcripts repressed in proteinuric 
glomerulopathies with glomerular expression and glucocorticoid-induced regulation would 
give new insights to podocyte dysfunction. The glucocorticoid-induced leucine zipper 
TSC22D3 showed a significant repression in all three proteinuric diseases and was found to 
be expressed in podocytes of human nephrectomy biopsies. In chapter VI, the preliminary 
results of the second candidate gene transcript TSC22D3 are presented. Several studies 
indicated that TSC22D3 has a key role in anti-inflammatory and immunosuppressive 
processes. Different research approaches from cell culture experiments with multiple rodent 
and human cell lines to an experimental model of Drosophila flies were pursued with 
promising results. 
 
 
This work contains both published data (chapters I-IV) and preliminary results (chapters V-
VI).  
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CHAPTER V 
  
 
 
PRELIMINARY DATA: Functional studies on periostin 
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Cell cycle analysis and apoptosis 
Our previous studies showed that periostin induces cell proliferation and decreases the 
number of apoptotic cells (see chapter III) [196]. 
 
Material and Methods 
To study the effect of periostin on apoptosis, cell cycle analyses were performed by flow 
cytometry using propidium iodide and annexin V binding (eBioscience, Vienna, Austria). 
Human and murine mesangial cells (HMC; MMC) were plated on six-well plates. Cells were 
starved in medium (DMEM; Gibco, Invitrogen) containing 0.5% fetal bovine serum (FBS) 24 
hours before exposure for 48 hours to human periostin (100-1000 ng/ml; Biovendor, 
Heidelberg, Germany) or vehicle. Induction of apoptosis as positive control was performed as 
described in Lorz et al. [197].  
Statistical analyses (Kruskall-Wallis and Mann-Whitney U-tests) were performed using SPSS 
17.0 (Spss., Chicago, IL). P values < 0.05 were considered to indicate statistically significant 
results.  
 
Results 
Mechanisms that promote cell survival or prevent apoptosis are considered to promote cell 
proliferation. An antiapoptotic effect of periostin was found in our experiments (Figure 4). 
The number of apoptotic cells was reduced by 9.3% and 9.7% when incubated with 100 ng/ml 
and 1000 ng/ml periostin, respectively. This result corresponded to other reports with 
different cell types [198, 199].  
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Figure 4: Effects of periostin on apoptosis 
Cultured human mesangial cells (HMC) were incubated in 0.5% FBS control media or media containing 100 
ng/ml to 1000 ng/ml recombinant periostin. The number of apoptotic cells was reduced when incubated with 
recombinant periostin. n=2; n.s. not significant 
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Periostin-deficient mice 
In our human renal biopsies periostin was expressed in healthy human glomeruli. In patients 
with proteinuric glomerulopathies we found increased expression in glomeruli and in the 
fibrotic tubular interstitium.  
 
Material and Methods 
Periodic acid-Schiff (PAS) silver staining was performed to study the renal morphology in 
periostin-deficient mice. Immunohistochemistry for periostin was established in murine renal 
tissue as previously described [200]. In brief, dewaxed and rehydrated tissue sections were 
incubated in 3% hydrogen peroxide to block endogenous peroxidases. The Avidin/Biotin 
blocking kit was used to block endogenous biotin (Vector Laboratories, Burlingame, CA). 
Antigen retrieval was performed in a microwave oven in hydrochloric acid solution with a pH 
of 0.9 for periostin and in an autoclave oven in an antigen unmasking solution with a pH of 6 
(Vector Laboratories) for -smooth muscle actin (-SMA, M0851; DAKO, Glostrup, 
Denmark), respectively. The primary antibody was applied for 1 hour, and incubation with the 
biotinylated secondary antibody for 30 minutes was followed by the ABC reagent (Vector 
Laboratories). 3,3′-Diaminobenzidine (Sigma, Taufkirchen, Germany) with metal 
enhancement (resulting in a black product) was used as a detection system. A monoclonal rat 
anti-mouse periostin antibody was used (MAB3548; R&D Systems, Germany). Blocking 
experiments were performed with a recombinant periostin protein (2955-F2; R&D Systems), 
which completely abolished the signal.  
 
Renal tissue from periostin-deficient and wildtype mice (4- and 12-weeks old) were received 
from Dr. Simon Conway (Herman B Wells Center for Pediatric Research, Department of 
Pediatrics, Indiana University of Medicine, Indianapolis) [201]. 
Serum analyses from mice were performed with the Piccolo Xpress chemistry analyzer 
(Abaxis, Griesheim, Germany) using the renal function panel. Serum samples from wildtype 
(6-weeks old n=14, 24-weeks old n=9) and periostin-deficient mice (6-weeks old n=17, 24-
weeks old n=9) were obtained from Dr. Nicolas Bonnet and Dr. Serge Ferrari (University 
Geneva Hospital, Service of Bone Diseases, Switzerland) [202]. 
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Results 
Periodic acid-Schiff (PAS) silver staining and immunohistochemistry for -smooth muscle 
actin (-SMA) was performed in murine renal tissue of wildtype and periostin-deficient mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: PAS silver staining 
PAS silver staining of renal tissue from adult (12-weeks old) mice showed enlarged glomeruli in periostin-
deficient (postn -/-) mice (B) compared to wildtype (WT) mice (A). 40x  
Immunohistochemistry staining for -smooth muscle actin (-SMA) showed a proliferative mesangium (D) in 
the periostin-deficient glomeruli. 
postn -/- WT 
postn -/- WT 
A B 
C D 
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To study the expression and localization of the periostin protein in renal tissue from healthy 
wildtype mice, immunohistochemistry was established on formalin-fixed, paraffin-embedded 
murine renal tissue (Figure 6).  A similar staining pattern as in human renal tissue was found. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Localization of periostin in murine renal tissue 
Adult murine renal tissue was used to establish a staining protocol for periostin in mice. Periostin was found to 
be expressed along the Bowman’s capsule and in regions with interstitial fibrosis. 20x 
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As our previous in-vitro and ex-vivo human studies on periostin showed that serum marker 
levels differentiate, further studies on murine serum samples were performed. We compared 
serum data from wildtype mice and periostin-deficient mice with age of six and twelve weeks.  
 
 
 
 
 
Figure 7: Blood urea nitrogen level 
The blood urea nitrogen (BUN) level was significantly higher in adult periostin-deficient mice (postn -/-) 
compared to wildtype mice. * p<0.05 
 
 
Unexpected, but according to our previous renal morphology studies periostin-deficient mice 
showed worse renal function (Figure 5 and 7). As example the blood urea nitrogen (BUN) 
value was increased which indicates an existing renal damage. The level of BUN was 
significantly higher in adult periostin-deficient mice 21.4 ± 4.7 mg/dl versus wildtype 17.2 ± 
4.1 mg/dl (Figure 7). 
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This unexpected result accorded with our renal biopsy studies as the PAS silver staining 
revealed worse renal constitution in periostin-deficient mice (Figure 5). Comparison of the 
other serum data showed no significant aberrations (Table 1). 
 
 
Table 1: Renal values 
Elevated blood urea nitrogen level was measured in periostin-deficient mice (postn -/-) compared to wildtype 
mice. 
postn -/- 6-weeks old n=17; wildtype 6-weeks old n=14; postn -/- 24-weeks old n=9; wildtype 24-weeks old n=9 
 
Abbreviations: GLU=Glucose; BUN=Blood Urea Nitrogen; CA=Calcium; CRE=Creatinine; ALB=Albumin; 
PHOS=Phosphorus; Na+=Sodium; K+=Potassium; Cl-=Chloride; tC02=Total Carbon Dioxide 
 
Genotype Age GLU [mg/dl] BUN [mg/dl] CA [mg/dl] CRE [mg/dl] ALB [g/dl] 
postn -/- 6 weeks 188.4 ± 43.8 19.2 ± 3.8 9.5 ± 0.3 <0.2 1.9 ± 0.1 
wildtype 6 weeks 218.4 ± 36.2 19.9 ± 2.3 9.8 ± 0.4 <0.2 1.9 ± 0.1 
postn -/- 24 weeks 169.4 ± 21.9 21.4 ± 4.7 8.7 ± 0.5 <0.2 1.9 ± 0.2 
wildtype 24 weeks 171.0 ± 23.1 17.2 ± 4.1 8.6 ± 0.3 <0.2 1.7 ± 0.3 
       
       
Genotype Age PHOS  [mmol/l] Na+ [mmol/l] K+ [mmol/l] Cl- [mg/dl] tCO2  [mmol/l] 
postn -/- 6 weeks 8.6 ± 0.8 145.2 ± 1.7 5.4 ± 0.5 102.8 ± 1.0 19.5 ± 3.2 
wildtype 6 weeks 7.8 ± 0.7 145.4 ± 2.9 5.3 ± 0.3 103.1 ± 2.4 19.5 ± 3.8 
postn -/- 24 weeks 6.1 ± 0.6 146.0 ± 1.7 6.7 ± 1.2 103.3 ± 2.0 13.0 ± 1.9 
wildtype 24 weeks 6.5 ± 1.0 144.3 ± 3.0 5.8 ± 0.5 103.4 ± 1.9 13.9 ± 2.2 
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CHAPTER VI 
 
 
 
PRELIMINARY DATA: TSC22D3 – a glucocorticoid-induced leucine 
zipper repressed in renal disease 
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INTRODUCTION 
 
Glucocorticoids are involved in physiological regulation of a variety of processes, including 
immune responses, metabolism, cell growth, and development [203]. Patients with renal 
diseases are initially treated with glucocorticoids and a majority of them respond rapidly with 
improvement of proteinuria or even full remission.  
 
On our transcriptomic approach to study mechanisms involved in renal diseases, TSC22D3 
was found to be significantly repressed in the main acquired proteinuric diseases MCD, FSGS 
and MGN. TSC22D3, also known as glucocorticoid-induced leucine zipper (GILZ), was first 
identified in a study with thymocytes and T-cells [204]. Several studies indicated that 
TSC22D3 has a key role in anti-inflammatory and immunosuppressive processes. In the 
kidney, up-regulation of TSC22D3 was stimulated by aldosterone in a mouse kidney 
collecting duct principal cell (mCCD) line. Furthermore, TSC22D3 was associated with up-
regulation of the α-subunit of the renal ENaC channel [205].     
 
The main aim of the study was to investigate the role of TSC22D3 in cultured glomerular 
epithelial cells, so called podocytes. In addition to the in-vitro experiments also very pre-
functional studies in drosophila flies were initiated. 
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MATERIAL AND METHODS 
 
Renal Biopsies for mRNA Analysis and Quantitative Real-Time RT-PCR 
As described before in Sen et al. [196]. Predeveloped TaqMan reagents were used for human 
TSC22D3 (Hs00933671_m1; Applied Biosystems Europe, Rotkreuz, Switzerland). For the 
human TSC22D3 variants the following oligonucleotide primers and probe were used: 
TSC22D3-1 sense primer 5’-ACCAGACCATGCTCTCCATC-3’, antisense primer 5’-
GGCCTGTTCGATCTTGTTGT-3’, fluorescence labeled probe (6-FAM) 5’-
TCTTCTTCCACAGTGCCTCC-3’; TSC22D3-2 sense primer 5’-
CTTGGAGGGGATGTGGTTT-3’, antisense primer 5’-GGCCTGTTCGATCTTGTTGT-3’, 
fluorescence labeled probe (6-FAM) 5’-AAGCTGGACAACAGTGCCTC-3’; TSC22D3-3 
sense primer 5’-GCTTACCAGCCGAGAAGGA-3’, antisense primer 5’-
GGCCTGTTCGATCTTGTTGT-3’, fluorescence labeled probe (6-FAM) 5’-
TAGCTAGCTTCAGAGCCGGTGCCTC-3’. The expression was normalized by two 
reference genes, 18S rRNA and GAPDH.  
 
Immunohistochemistry 
Dewaxed and rehydrated tissue sections were incubated in 3% hydrogen peroxide to block 
endogenous peroxidases. The Avidin/Biotin blocking kit was used to block endogenous biotin 
(Vector Laboratories, Burlingame, CA). Antigen retrieval was performed in a microwave 
oven in an antigen unmasking solution with a pH of 6 (Vector Laboratories). The primary 
antibody (1:50; 14-4033-80; eBioscience, San Diego, CA) was applied for 1 hour, and 
incubation with the biotinylated secondary antibody for 30 minutes was followed by the ABC 
reagent (Vector Laboratories). 3,3’-Diaminobenzidine   (Sigma, Taufkirchen, Germany) with 
metal enhancement (resulting in a black product) was used as a detection system. Human 
transplant nephrectomy tissue and murine renal tissue were used to establish the staining 
protocol.  
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Immunofluorescence 
Multicolor immunofluorescence was performed for TSC22D3 and Wilms tumor 1 (WT1) on 
kidney transplant nephrectomy tissue. The monoclonal antibody for TSC22D3 (1:500; 
H00001831-M01; Abnova, Walnut, CA) was visualized with a Cy3-labeled secondary 
antibody (Invitrogen, Basel, Switzerland). WT1 (sc-192; Santa Cruz Biotechnology, Santa 
Cruz, CA) was visualized by a biotinylated secondary antibody and labeled with fluorescein 
isothiocyanate bound to streptavidin (Vector Laboratories).  
 
Western Blot Analysis 
Cultured human (AB81) and murine (K5P5) podocytes were harvested with 
radioimmunoprecipitation assay buffer (Ripa) composed of 150 mmol/L NaCl, 1% (v/v) 
Nonidet P40, 0.5% (v/v) sodium deoxycholate, 0.1% (v/v) SDS, and 50 mmol/L Tris (pH 8) 
or cell lysis buffer (CLB) composed of 1 mmol/L EDTA (pH 8), 400 mmol/L NaCl, 0.1% 
(v/v) Nonidet P40 and 10 mmol/L Tris (pH 8) (Gibco, Invitrogen). The protein concentrations 
of the lysates were determined by the Bradford method (Bio-Rad Laboratories, Hercules, 
CA). Extracted proteins were boiled in loading buffer for 5 minutes, resolved by 15% SDS-
polyacrylamide gel electrophoresis under reducing conditions, and transferred to an 
Immobilon-P membrane (Millipore, Eschborn, Germany). Membranes were blocked for 1 
hour with Tris-buffered saline/3% fat-free skim milk and then incubated with a monoclonal 
rat antibody raised against human/mouse TSC22D3 (2 μg/ml; eBioscience) overnight at 4°C 
and rinsed with Tris-buffered saline containing 0.1% Tween. For detection, a horseradish 
peroxidase-linked anti-rat IgG antibody (1:10’000, 1 hour at room temperature; eBioscience) 
and enhanced chemiluminescence substrate (PerkinElmer Life and Analytical Sciences, 
Waltham, MA) were used. The protocol was also used with a polyclonal rabbit antibody 
raised against mouse TSC22D3 (1:3’000, obtained from Dr. David Pearce; University of 
California, San Francisco, USA) [206]. 
 
Cell Culture 
Murine podocytes (K5P5) were grown on type 1 collagen-coated flasks in RPMI-1640 
medium (Gibco, Invitrogen) containing 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin (P/S; Gibco, Invitrogen). Cells were incubated at 37°C in a humidified 
atmosphere of 5% CO2 in air for a minimum of five days to differentiate. 
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Dexamethasone stimulation 
Murine podocytes (K5P5) were starved in serum-free medium 24 hours before incubation 
with 1000 nM Dexamethasone (D4902; Sigma, Taufkirchen, Germany) for 8, 12, and 24 
hours, respectively. This time-dependent analysis showed highest induction at 12 hours, 
hence dose-dependence was tested at 12 hours with 0.1 to 1000 nM Dexamethasone. Total 
cellular RNA was extracted using Qiagen RNeasy kit (Qiagen, Hombrechtikon, Switzerland). 
The mRNA expression was analyzed by real-time RT-PCR. Predeveloped TaqMan reagents 
were used for murine Tsc22d3 (Mm00726417_s1; Applied Biosystems Europe, Rotkreuz, 
Switzerland). 
 
Statistics 
Statistical analyses (Kruskall-Wallis and Mann-Whitney U-tests) were performed using SPSS 
17.0 (Spss., Chicago, IL). P values < 0.05 were considered to indicate statistically significant 
results.  
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RESULTS 
 
Glomerular expression of TSC22D3 mRNA  
 
To confirm that TSC22D3 mRNA is overrepresented in healthy glomeruli compared to the 
tubulointerstitial compartment, we performed quantitative real-time RT-PCR for TSC22D3 
mRNA on microdissected glomeruli and tubulointerstitium of pretransplant biopsies from 
living renal allograft donors (n=13). Consistent with the data of Lindenmeyer et al. [207], 
TSC22D3 demonstrated a 3.9-fold (± 1.1, p < 0.01) higher expression in microdissected 
glomeruli than in tubulointerstitial specimens (Figure 8). Additional quantitative real-time 
RT-PCR for the three splicing variants of TSC22D3 confirmed the result.   
 
 
 
 
Figure 8: TSC22D3 in healthy human kidneys 
Expression of TSC22D3 mRNA in microdissected samples of allograft donors normalized to the tubulointerstitial 
expression. **p<0.01; ***p<0.001 
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TSC22D3 in healthy kidneys 
 
Two antibodies (eBioscience and Dr. Pearce group) were used to localize TSC22D3 by 
immunohistochemistry in human und murine renal tissue. In human transplant nephrectomies 
podocytes and some distal tubules were positive for TSC22D3; in murine renal  tissue  only  
the  distal  tubules  were  positive (Figure 9a). 
 
 
 
 
 
 
 
 
 
 
 
 
 
             
 
 
Figure 9a: TSC22D3 staining 
To study the renal localization of TSC22D3, immunohistochemistry was performed with a monoclonal antiserum 
against TSC22D3 (eBioscience) on renal tissue. 40x 
(A) In human transplant nephrectomies podocytes and some distal tubules were positive for TSC22D3. 
(B) In murine renal tissue only the distal tubules were positive. 
 
A B 
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TSC22D3 localization in the human glomerulus 
 
By co-immunofluorescence with WT1, a podocyte marker, a clear overlap with TSC22D3 
was seen (Figure 9b).  
 
 
         
 
Figure 9b: Co-immunofluorescence for TSC22D3 and WT1 
A human transplant nephrectomy was stained for TSC22D3 (A) and WT1 (B). The merge (C) indicated a clear 
overlap of both signals. 
 
 
According to the staining pattern, human and murine podocyte cell lysate were found to be 
positive for TSC22D3 by Western blot analysis (Figure 10).  
WT1 TSC22D3 overlay A B C 
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TSC22D3 in human and murine podocytes 
 
 
(A)        (B) 
 
 
 
 
(C) 
 
 
 
(D) 
 
 
 
 
 
Figure 10: Western blot analysis of TSC22D3 with different antibodies 
(A), (B) Multiple unspecific bands were found with commercial available antibodies to TSC22D3 from Abnova 
and Santa Cruz. AB81, h63=human podocytes; K5P5=murine podocytes; mCCD=murine cortical collecting 
duct cells; HMC=human mesangial cells; RC=recombinant protein for TSC22D3 
(C), (D) A single band of the expected size was found in a human (AB81) and murine podocyte cell line (K5P5); 
a murine cortical collecting duct cell line (mCCD) served as positive control. Antibodies obtained from 
eBioscience and Research Group Dr. Pearce, San Francisco, USA [206]. 
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TSC22D3 in glomerulopathies  
 
In Figure 11, the expression of TSC22D3 mRNA in different proteinuric 
glomerulonephropathies is shown as fold-change compared with living donors (LD). 
Corresponding to our previously reported microarray data, the mRNA expression was found 
to be significantly decreased in the progressive glomerulonephropathies such as LN, FSGS 
and MGN (p < 0.001) but not significantly in non-progressive MCD.  
 
 
 
 
 
Figure 11: TSC22D3 in glomerulonephropathies 
Expression of TSC22D3 mRNA in different renal diseases normalized to healthy living donors (LD) (LN: Lupus 
nephritis III-IV; FSGS: focal-segmental glomerulosclerosis; MGN: membranous glomerulonephropathy; MCD: 
minimal change disease). ***p<0.001  
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TSC22D3 in glomerulopathies treated with corticosteroids 
 
Interestingly, the renal biopsies from patients diagnosed with a progressive proteinuric 
glomerulopathy preceding glucocorticoid treatment were prone to a higher mRNA expression 
level (Figure 12) than the untreated group. This result corresponds to previous studies that 
considered TSC22D3 as a glucocorticoid-inducible gene [208]. 
 
Figure 12: TSC22D3 in glomerulonephropathies treated with corticosteroids 
Expression of TSC22D3 mRNA in different renal diseases treated with steroids normalized to the disease group 
without steroids (LN: Lupus nephritis III-IV; FSGS: focal-segmental glomerulosclerosis; MGN: membranous 
glomerulopathy). n.s. not significant 
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 In-vitro stimulation experiments 
 
TSC22D3 was originally discovered in studies aimed at characterizing genes targeted by 
dexamethasone. In-vitro stimulation experiments of murine podocytes by dexamethasone 
resulted in a time- and dose-dependent induction of TSC22D3 (Figure 13). 
 
 
 
 
Figure 13:  In-vitro stimulation by dexamethasone  
Dexamethasone enhanced Tsc22d3 mRNA expression in murine epithelial cells (podocytes) time- and dose-
dependently. n=3, shown are the means and standard deviations, n.s. not significant 
n.s. 
n.s. 
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Functional studies in drosophila melanogaster 
 
Weavers et al. described a podocyte-like cell type in Drosophila melanogaster. The podocyte 
and nephrocyte filtration barriers are morphologically and functionally similar (Figure 14). 
The nephrocyte is very similar to the mammalian podocytes, including the nephrin-based slit 
diaphragm and is a simple model to study podocyte biology. Slit diaphragm specific genes 
such as nephrin (kirre) and podocin (mec2) are all expressed by the nephrocytes and loss of 
function leads to loss of slit diaphragm. A functional test of drosophila nephrocytes may be 
performed with the silver-nitrate (AgNO3) method as dysfunctional nephrocytes are unable to 
eliminate the toxic AgNO3 by endocytosis [209]. 
 
 
 
 
 
Figure 14:  
Vertebrate nephron (a), glomerular filtration barrier (b), insect excretory system (c) and nephrocyte filtration 
barrier (d). bm=basement membrane; fp=foot process; nd=nephrocyte diaphragm; sd=slit diaphragm. Taken 
from Weavers et al., Nature 2009 [209]. 
 
 
The group of Hugo Stocker identified bunched A (BunA), the drosophila homolog of 
TSC22D3, to promote cellular growth [210]. BunA deletion mutants showed growth deficits 
and their eyes were smaller with a reduced cell size compared to wildtypes [211].  
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In our very preliminary studies, cDNA samples from two BunA (drosophila homolog of 
TSC22D3) mutants and wildtype flies were analyzed (obtained from the Group of Dr. Hugo 
Stocker) [211]. Real-time RT-PCR showed a reduction of BunA expression in both mutants 
confirming the deletion of BunA specific sequence. To further study the role of the bunched 
isoforms in drosophila, larvae were fed with normal yeast, high salt yeast or starved (n=1). A 
decreased expression for BunA and BunB was detected in mutants with BunC deletion 
compared to the controls (wildtype) under normal feeding conditions suggesting a functional 
interference among the different isoforms. 
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DISCUSSION AND OUTLOOK 
Proteinuric glomerulopathies are associated with an increased risk for the development of 
renal failure. The molecular mechanisms leading to proteinuric glomerulopathies are intensely 
researched and progress has been made in diagnostic analysis and medical treatment. 
Nevertheless, the identification of responsible gene transcripts is still needed to understand 
the underlying biological processes involved in glomerular pathobiology. Several studies 
found genes that are responsible for a certain renal disease [212, 213]. 
The primary aim of these PhD project was to find candidate gene transcripts and to analyze 
the related biological processes involved in human proteinuric glomerulopathies.  
 
For that purpose, we first generated a dataset of gene transcripts specifically enriched in the 
renal glomerulus: 
 
PUBLICATED DATA (CHAPTERS I-IV) 
REGGED – a unique glomerulus-enriched dataset 
In chapter I, we started with the comparison of microarray gene expression data from human 
glomeruli and tubulointerstitium to generate a human glomerulus-enriched gene expression 
dataset (REGGED). Comparison with an earlier report of He et al. showed that our database 
with 677 genes is highly enriched for known podocyte- and glomerulus-enriched genes such 
as MYH9 [214]. REGGED allowed us to select gene transcripts expressed in the human 
glomerulus and to compare these gene transcripts to our gene expression profiles of different 
glomerulopathies (ERCB-KFB).  
Several studies confirmed their candidate gene transcripts to be enriched in the glomerulus 
with our dataset [215, 216]. Hwang et al. strengthened their study on anomalies of the kidney 
and urinary tract as podocytes were described and confirmed as ROBO2-expressing cells 
[216]. They identified two mutations in SRGAP1, an important player in the SLIT2-ROBO2 
signaling pathway during the kidney development. Interestingly, in our study ROBO2 mRNA 
was expressed low in diabetic nephropathy compared to control pretransplant biopsies. From 
previous rodent studies it is known that disruption of ROBO2 is associated with urinary tract 
anomalies [217, 218]. 
Other reports focused on glomerulus-specific transcripts and obtained a very similar list with 
known glomerular expressed genes such as CDKN1, PLA2R1, NPHS1 and NPHS2 [219].  
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REGGED identified established and novel gene transcripts expressed in the human 
glomerulus and the subsequent systematic analyses of the selected gene transcripts are part of 
this doctoral thesis. 
 
 
Hypoxia – a promotor of glomerular damage in nephrosclerosis 
Chronic hypoxia contributes to renal fibrosis and was hypothesized to be involved in 
nephrosclerosis (NSC), also known as hypertensive nephropathy. To comprehend the 
biological processes involved in hypoxia-related glomerulosclerosis, we performed specific 
studies in chapter II. 
In human nephrosclerosis (NSC), a cause for end-stage renal disease, hardening of the small 
blood vessels and association with diabetes and hypertension are characteristic. Chronic 
hypoxia was proposed to be coincidentally cause and consequence of chronic kidney disease 
and renal failure [220-222]. Reduced oxygen delivery leads to activation of pathological 
processes such as development of interstitial renal fibrosis and vasoconstriction. 
In an experimental unilateral ureteral obstruction (UUO) model, epithelial HIF1 (hypoxia 
inducible factor) has been identified as a promotor of renal fibrosis [113]. Recently, Shved et 
al. found significant correlations of HIF target genes with eGFR in patients with chronic 
kidney disease [223]. Hypoxic conditions led to HIF activation and known HIF target genes 
such as CXCR4 were increased. In our patients with NSC, induction of CXCR4 mRNA was 
seen. In kidney biopsies of these patients CXCR4 was localized to podocytes with a positive 
nuclear staining for HIF1α suggesting a transcriptional activity of HIF1α. These findings 
indicated that hypoxic processes contribute both to tubulointerstitial fibrosis and also to 
glomerular damage.  
 
 
Periostin – a matricellular protein contributing to the progression of human 
nephropathies 
In a further step, our REGGED dataset was used to select a glomerular gene transcript with 
the highest induction mainly in the progressive glomerulopathies FSGS and MGN. 
Progressive kidney disease is characterized by extracellular matrix deposition, inflammatory 
processes and loss of nephrons [71]. Earlier studies identified matricellular proteins such as 
SPARC to be regulators of fibrosis, cell-matrix changes and angiogenesis [195].  
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In our dataset the expression of matricellular proteins were low in healthy kidneys but very 
high in progressive glomerulopathies. We therefore selected the matricellular protein periostin 
(POSTN) with the highest fold of expression as an interesting candidate gene transcript for 
our studies in human glomerulopathies (chapter III). It is known that periostin is involved in 
fibrotic alterations in cardiac valves and bone tissues [224, 225]. In our study, progression of 
renal disease correlated significantly to the expression of periostin. Guerrot et al. also 
demonstrated in an experimental model a correlation of periostin expression and progression 
of hypertensive nephropathy [226]. Similarly, current data revealed a correlation between 
periostin renal biopsy staining score and renal function in lupus nephritis patients [227]. This 
result is consistent with our highest periostin mRNA induction in our lupus nephritis patients 
compared to the living donors. Satirapoj et al. found excretion of urinary periostin in 
proteinuric and non-proteinuric CKD patients and higher urinary periostin levels in chronic 
allograft nephropathy patients compared to transplant controls [228, 229]. Furthermore, 
urinary periostin correlated with serum creatinine. Thus, urinary periostin may be a promising 
biomarker of progressive renal injury. Other studies in a polycystic kidney disease mouse 
model showed that periostin-deficient mice had a reduction of cysts and less interstitial 
fibrosis leading to a longer survival rate [230].  
Further investigation with clinical and histological follow-up data from our glomerulopathy 
patient cohort may bring new insights to progression of disease and define disease specific 
expression profiles of periostin in CKD patients.  
 
In chapter IV, we continued our studies on periostin by performing staining series on biopsies 
from end-stage renal disease patients under peritoneal dialysis (PD) treatment. A complication 
of this treatment for end-stage renal disease (ESRD) patients is peritoneal fibrosis and 
encapsulating peritoneal sclerosis (EPS).  In our EPS biopsies the periostin-positive area were 
larger and more fibrotic than in control biopsies. Nam et al. [231] found increased expression 
of periostin in the peritoneum in mice treated with PD solution. Corresponding to our results 
the thickness of the submesothelial layer was also increased and more fibrotic. The 
intraperitoneal administration of a periostin-binding DNA aptamer (PA) abolished the 
changes. This raises the question whether a periostin-binding DNA aptamer could be a 
potential therapeutic treatment for the prevention of fibrosis in PD patients. 
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In addition, we found significantly increased periostin levels in the dialysate of PD patients 
without signs of EPS. Interestingly, only low levels of periostin could be detected in dialysate 
of PD patients with already developed EPS. Consequently, measuring of periostin 
concentration in dialysate might be used as a biomarker indicating progression of 
complication in PD treatment. 
 
Nevertheless, therapeutic options for renal fibrosis are still lacking. Periostin is an obvious 
marker for progression of proteinuric renal disease and inhibition of periostin expression in 
early stages of CKD development could be a therapeutic approach. 
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PRELIMINARY DATA (CHAPTERS V-VI) 
Periostin – a matricellular protein involved in renal injury 
Our previous studies (chapters III and IV) aimed us to study further on periostin. Periostin 
plays an important role in cell-matrix interactions and in the development of fibrosis. This 
matricellular protein has been studied intensely in bone, heart and lung. In chapter V, we 
performed pre-functional studies on periostin: 
 
Periostin was found to be highly expressed in different cancer cell lines [232-234] where it 
was proposed to be an important factor during cell proliferation and cell migration [235, 236]. 
In our cell cycle studies with human and murine mesangial cells periostin showed an 
antiapoptotic effect (Figure 4). This result corresponded to other reports with different cell 
types [198, 199]. Liu et al. inhibited periostin gene expression via RNA interference. 
Proliferation and invasion of cancer cells were suppressed [237]. This may be a new research 
approach to pursue in progressive chronic kidney disease. It would be necessary to study 
whether total inhibition of periostin expression would affect the progression of human renal 
disease. Existing renal fibrosis cannot be revoked but slowing the development of fibrosis in 
patients with progressive glomerulopathies could be life prolonging. Earlier studies 
demonstrated that disruption of the TGF-/Smad3 signaling pathway protected from renal 
tubulointerstitial fibrosis [108, 238]. A correlation was shown between periostin and 
induction of the TGF- signaling pathway. In a diabetic mouse model, the matricellular 
protein SPARC was associated with glomerulosclerosis and tubulointerstitial damage due to 
increased TGF-1 expression [194]. In addition, another matricellular protein 
thrombospondin was also shown to change renal pathophysiological processes via activation 
of TGF- [239]. 
 
In our human renal biopsies periostin was expressed in healthy human glomeruli. We found 
increased expression of periostin in the glomeruli and also in the fibrotic tubular interstitium 
of patients with progressive glomerulopathies (chapter III). Unexpectedly, in our studies the 
renal morphology in periostin-deficient mice showed worse renal constitution compared to 
wildtype mice. This result accorded with the increased blood urea nitrogen (BUN) levels of 
adult periostin-deficient mice as elevated BUN levels suggest renal function alterations. The 
other serum values were comparable and inconspicuous. Additionally, future examination of 
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the urinary samples of our periostin-deficient mice is required as it would be interesting to 
know whether different excretory products are occurring. 
Our preliminary studies on periostin-deficient mice indicated that periostin might be 
necessary for the renal development. Although mice lacking the periostin gene showed less 
interstitial fibrosis and inflammation in an UUO model, periostin seems to be important for 
the regulation of cell-matrix interactions and accumulation [240]. Periostin-deficient mice 
showed anomalies in teeth and periodontal apparatus and the survival rate was reduced 
compared to the wildtype littermates [201]. This potential developmental relevance of 
periostin for the kidneys corresponded to our immunohistochemical stainings of human fetal 
kidney tissue (not shown) where periostin was found to be strongly present in the developing 
renal region. 
 
In summary, in different animal models of CKD expression of periostin is constantly 
associated with inflammatory processes, interstitial fibrosis and decline of renal function 
[226, 228, 230, 240, 241]. Further studies in renal morphology and physiology in periostin-
deficient mice with or without an experimental nephropathy would give new insights to the 
role of periostin in the kidney.  
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TSC22D3 – a glucocorticoid-induced leucine zipper involved in renal injury 
From clinical data, it is known that patients with certain glomerulopathies such as minimal 
change disease (MCD) respond positively with full remission to corticosteroid therapy [242, 
243]. A primary dysfunction of the podocytes such as foot process effacement is leading to 
proteinuria and is specific for those corticosteroid-sensitive glomerulopathies. Seeking for a 
corticosteroid-stimulated REGGED gene transcript, we found TSC22D3 mRNA to be 
significantly decreased in the progressive glomerulopathies such as LN, FSGS and MGN.  
In chapter VI, the second candidate gene transcript TSC22D3 was studied ex-vivo in humans 
and in-vitro in human and murine cells. TSC22D3, also known as glucocorticoid-induced 
leucine zipper (GILZ), was first found to be expressed in lymphocytes from thymus [204]. 
Murine thymocytes stimulated with the corticosteroid dexamethasone showed an increased 
expression of TSC22D3 and cells overexpressing TSC22D3 were resistant to TCR/CD3-
activated apoptosis. Asselin-Labat et al. showed that TSC22D3 delays apoptosis in activated 
T lymphocytes and that interleukins induce the expression of TSC22D3 [208]. 
 
In our studies, TSC22D3 was localized in podocytes and distal tubules but not in mesangial 
cells. This localization of TSC22D3 in distal tubules in murine and human tissue 
corresponded to earlier studies with mouse cortical collecting duct cells (mCCD) [244]. 
Hormone-regulated sodium (Na+) transport is essential for the control of circulatory volume, 
blood pressure and extracellular fluid composition. A correlation between TSC22D3 mRNA 
expression and urinary excretion of sodium and potassium was found in adrenalectomized 
rats after treatment with aldosterone and dexamethasone [205]. Moreover, the transepithelial 
transport through ENaC is inhibited by activated ERK1/2 and Tsc22d3 stimulates this 
transport by inhibition of ERK activation [206]. 
The increasing effect of corticosteroids on mRNA levels in glomerulopathies prompted us to 
in-vitro stimulation experiments. Incubation of murine podocytes with dexamethasone 
resulted in a time- and dose-dependent induction of Tsc22d3 mRNA. This result accorded 
with the study in a murine T lymphocyte cell line [208]. Asselin-Labat et al. showed that 
addition of RU-486, a glucocorticoid receptor antagonist, totally inhibited dexamethasone-
induced Tsc22d3 expression. Tsc22d3 induction therefore requires a functional glucocorticoid 
receptor. As a consequence, TSC22D3 acts as a mediator for anti-inflammatory and 
immunosuppressive activities. 
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Experimental animal models to investigate the role of TSC22D3 in the kidney are only a few 
available [245-247]. Mice lacking Tsc22d3 have electrolyte abnormalities, increased plasma 
potassium concentration and alterations in sodium delivery to the ENaC.  
Weavers et al. [209] described a podocyte-like cell type, the Drosophila nephrocytes, which 
acts as a filtration barrier. Functional studies can be performed with the silver-nitrate method 
to find differences among the mutant and wildtype flies in renal function. In Drosophila 
melanogaster, the TSC22D3 homolog bunched (Bun, Shs) has been examined with different 
feeding conditions [210, 248]. In our very preliminary studies real-time RT-PCR showed a 
decreased expression for BunA and B in mutants with BunC deletion compared to the 
controls under normal feeding conditions suggesting functional interference among the 
different isoforms. We speculated that mutants with deletion of bunched have dysfunctional 
nephrocytes and therefore would be unable to eliminate toxic substances such as silver-nitrate 
by endocytosis. Various experimental approaches with different feeding conditions and 
addition of glucocorticoids should be pursued to achieve advanced knowledge about its renal 
function. 
A further interesting method to study podocyte dysfunctions was established in a zebrafish 
model. Sugano et al. followed a similar research approach to our TSC22D3 study by selecting 
a glomerulus-enriched REGGED gene transcript with glucocorticoid-induced regulation 
[249]. The glomerulus-enriched Rho-GTPase binding protein IQGAP2 was found to be 
expressed in human and zebrafish podocytes and a repressed gene expression was detected in 
biopsies of patients with nephrotic syndrome. In this experimental iqgap2-knockdown model 
a mild foot process effacement with impaired permeability of the glomerular filter was 
observed.  
 
In conclusion, we generated a unique glomerulus-enriched gene expression dataset and we 
found two candidate gene transcripts with promising molecular importance in proteinuric 
glomerulopathies. For Periostin, further functional studies in renal experimental models such 
as a periostin-overexpressing mouse and analyses of clinical follow-up data from patients 
with progressive glomerulopathies would give further insights to this matricellular protein.  
The glucocorticoid-induced gene transcript TSC22D3 may represent a therapeutic target for 
steroid-sensitive podocytopathies. Renal studies in the drosophila fly model with its 
malpighian tubule and nephrocytes or a knockdown model in zebrafish larvae could 
demonstrate the role of TSC22D3 in the renal system.  
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